| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/18/2000 | WO2000027832A2 Thiazole derivatives as ppar gamma ligands |
| 05/18/2000 | WO2000027823A1 Gastrin and cholecystokinin receptor ligands |
| 05/18/2000 | WO2000027822A2 Tricyclic pyrazole derivatives |
| 05/18/2000 | WO2000027820A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors |
| 05/18/2000 | WO2000027819A2 Antrhranilic acid amides and the use thereof as medicaments |
| 05/18/2000 | WO2000027811A1 Neurotrophic diamide and carbamate agents |
| 05/18/2000 | WO2000027808A1 N-arylsulfonyl amino acid omega amides |
| 05/18/2000 | WO2000027802A1 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| 05/18/2000 | WO2000027433A1 Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants |
| 05/18/2000 | WO2000027432A1 USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS |
| 05/18/2000 | WO2000027428A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
| 05/18/2000 | WO2000027422A2 Methods and compositions for treating or preventing peripheral neuropathies |
| 05/18/2000 | WO2000027414A2 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | WO2000027411A1 Composition made of plant extracts, especially for use in cancer treatment |
| 05/18/2000 | WO2000027404A1 Method for treating a patient with neoplasia by treatment with an anthracycline antibiotic |
| 05/18/2000 | WO2000027391A1 Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| 05/18/2000 | WO2000027389A1 Oxy-vanadium (iv) complexes having spermicidal activity |
| 05/18/2000 | WO2000027387A1 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis |
| 05/18/2000 | WO2000027383A1 Dysuria remedies |
| 05/18/2000 | WO2000027378A2 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 05/18/2000 | WO2000027363A1 Aerosols comprising nanoparticle drugs |
| 05/18/2000 | WO2000027359A1 An inhalation system |
| 05/18/2000 | WO2000027207A1 Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof |
| 05/18/2000 | WO2000027194A1 Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| 05/18/2000 | WO2000010590A3 Cancer treatment |
| 05/18/2000 | WO2000009734A3 Methods and compositions for use in spliceosome mediated rna trans-splicing |
| 05/18/2000 | WO2000009097A3 Pharmaceutical composition with antitumor activity on the basis of carboplatin |
| 05/18/2000 | WO2000008202A3 3-methylidenyl-2-indolinone modulators of protein kinase |
| 05/18/2000 | WO2000008141A3 Short oligonucleotides for the inhibition of vegf expression |
| 05/18/2000 | WO2000008140A3 Antisense oligonucleotides for the inhibition of vegf expression |
| 05/18/2000 | WO2000007544A3 Vitronectin receptor antagonists |
| 05/18/2000 | WO2000006140A3 Use of moclobemide for treating certain phsychiatric and medical disorders |
| 05/18/2000 | WO2000000514A3 Synthetic spiroketal pyranes as potent anti-cancer agents |
| 05/18/2000 | WO2000000207A9 Treatment of hyperproliferative disorders |
| 05/18/2000 | WO1999061467A3 Inhibition of the binding of protein tyrosine phosphatase pest to domains of signalling proteins |
| 05/18/2000 | WO1999058096A3 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| 05/18/2000 | DE19852245A1 5-Aminolävulinsäure-Nanoemulsion 5-aminolevulinic acid nanoemulsions |
| 05/18/2000 | DE19850718C1 Zellpermeabilität-vermittelndes Polypeptid Cell permeability-mediating polypeptide |
| 05/18/2000 | CA2351063A1 A system for administering a bioactive agent by inhalation comprising a lipid mixture comprising phosphatidylcholine |
| 05/18/2000 | CA2351019A1 Htfiiia human gene and coded htfiiia protein |
| 05/18/2000 | CA2350915A1 Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof |
| 05/18/2000 | CA2350429A1 Neurotrophic diamide and carbamate agents |
| 05/18/2000 | CA2350388A1 Human hydrolase proteins |
| 05/18/2000 | CA2350339A1 Pholasin |
| 05/18/2000 | CA2350235A1 Tricyclic pyrazole derivatives |
| 05/18/2000 | CA2350208A1 Antrhranilic acid amides and the use thereof as medicaments |
| 05/18/2000 | CA2350183A1 Use of an enterobacterium protein ompa for specific targeting towards antigen-presenting cells |
| 05/18/2000 | CA2350087A1 Chromosome 17p-linked prostate cancer susceptibility gene |
| 05/18/2000 | CA2350071A1 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis |
| 05/18/2000 | CA2350058A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
| 05/18/2000 | CA2349951A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 05/18/2000 | CA2349761A1 Corticosteroid synthesis-associated genes |
| 05/18/2000 | CA2349679A1 Modified exosomes and uses |
| 05/18/2000 | CA2349498A1 Methods and compositions for treating or preventing peripheral neuropathies |
| 05/18/2000 | CA2349449A1 Cell surface glycoproteins |
| 05/18/2000 | CA2348946A1 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 05/18/2000 | CA2348382A1 Chimeric parvovirus vectors and methods of making and administering the same |
| 05/18/2000 | CA2347916A1 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | CA2347847A1 A method of treating tumors using fas-induced apoptosis |
| 05/18/2000 | CA2346898A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors |
| 05/18/2000 | CA2346108A1 Gastrin and cholecystokinin receptor ligands |
| 05/18/2000 | CA2345620A1 Products and methods for brachytherapy |
| 05/18/2000 | CA2345459A1 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| 05/18/2000 | CA2318162A1 Oxy-vanadium (iv) complexes having spermicidal activity |
| 05/17/2000 | EP1001031A1 Parvovirus-vectors and their use |
| 05/17/2000 | EP1001030A1 Recombinant CELO virus and CELO virus DNA |
| 05/17/2000 | EP1001023A2 Frizzled-4, a putative Wnt-receptor |
| 05/17/2000 | EP1001022A1 CAMEL, an alternative translation product of the tumour antigen LAGE-1 |
| 05/17/2000 | EP1000930A2 Tachykinin antagonists |
| 05/17/2000 | EP1000166A2 Inhibitors of cell-cycle progression and uses related thereto |
| 05/17/2000 | EP1000078A1 HYBRID ANTHRACYCLINES FROM GENETICALLY ENGINEERED $i(STREPTOMYCES GALILAEUS) STRAINS |
| 05/17/2000 | EP1000075A1 Method of producing tiazofurin and other c-nucleosides |
| 05/17/2000 | EP1000054A1 Oligo-thiophenes useful as antimetastatic agents, a preparation thereof and pharmaceutical compositions containing them |
| 05/17/2000 | EP1000053A1 Macrocyclic lactones, compositions, and methods of use |
| 05/17/2000 | EP1000051A1 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/17/2000 | EP1000048A1 Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| 05/17/2000 | EP1000039A1 Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors |
| 05/17/2000 | EP1000038A1 Novel pyrimidin derivatives |
| 05/17/2000 | EP1000036A1 Hydantoin derivatives having an inhibitory activity for farnesyl transferase |
| 05/17/2000 | EP1000018A2 Urokinase inhibitors |
| 05/17/2000 | EP1000008A1 Novel thyroid receptor ligands and method |
| 05/17/2000 | EP0999835A1 Imidazole derivatives as mdr modulators |
| 05/17/2000 | EP0871437B1 Use of boswellic acid for treating brain tumours |
| 05/17/2000 | EP0804413B1 Nitrogen mustard prodrugs with novel lipophilic protecting groups, and processes for their production |
| 05/17/2000 | EP0773950A4 Linked peptide nucleic acids |
| 05/17/2000 | EP0726768B1 Use of nitric oxide releasing compounds for the manufacture of a medicament for protection in ischemia reperfusion injury |
| 05/17/2000 | EP0689426B1 Therapeutic agent for the treatment of melanomas |
| 05/17/2000 | CN1253586A Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription actor interactions |
| 05/17/2000 | CN1253566A Active substance and composition inhibiting tumorous proliferation in ectoderm derived tissues |
| 05/17/2000 | CN1253565A Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines |
| 05/17/2000 | CN1253561A Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3', 5'-monophosphate phosphodiesterase (cGMP PDE5) for treatment of sexual dysfunction |
| 05/17/2000 | CN1253559A Sulfonyl divalent aryl alpha-hydroxamic acid compounds |
| 05/17/2000 | CN1253557A Vitamin D3 analogs with bis C-20 side chains |
| 05/17/2000 | CN1253555A Novel 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same |
| 05/17/2000 | CN1253507A Acid-labile and enzymatically divisible dye structure for diagnosis with near infrared light and for therapy |
| 05/17/2000 | CN1253504A Cytokine related treatments of disease |
| 05/17/2000 | CN1253474A Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 05/17/2000 | CN1253014A Chinese-medicinal decoction for treating lung diseases |
| 05/17/2000 | CN1253003A Compound graceful jassamine preparation |
| 05/17/2000 | CN1252994A Mercury chloride injection |